



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

**CI-921: A CLINICAL, PHARMACOKINETIC AND
METABOLIC STUDY OF A POTENTIAL
NEW CYTOTOXIC AGENT.**

Being a thesis submitted for
the degree of
Doctor of Medicine
from the
University of Auckland

by

Janet Rea Hardy

Department of Clinical Oncology
Auckland Hospital
Auckland, New Zealand

1989

ABSTRACT

CI-921, an analogue of the antileukaemic agent amsacrine, was produced in an attempt to develop a cytotoxic agent with a broader spectrum of activity. CI-921 was selected for clinical trial on the basis of superior in vivo and in vitro solid tumour activity.

Sixteen patients with histologically documented cancer for which there was no conventional cytotoxic treatment were entered into a phase I trial. The dose of CI-921 was escalated from 39mg/m² to 810mg/m² (total dose divided over 3 days) and repeated 3 weekly. Neutropenia was the major dose limiting toxicity and defined a maximum tolerated dose of 810 mg/m².

Pharmacokinetic studies revealed a biexponential pattern of drug distribution with a distribution half-life of 2.6 h. The kinetics appeared linear over the dose range tested. Less than 1% of total drug was excreted in the urine.

Nineteen patients were entered into a limited phase II trial in non-small cell lung cancer using CI-921 at a dose of 648 mg/m² in the same 3-day schedule. One of the 16 evaluable patients achieved a partial response lasting five months. Myelosuppression was the predominant toxicity as in the phase I trial, but the degree of toxicity confirmed this dose as being suitable for further phase II trials. One patient had a grand mal seizure temporally associated with three of four courses of CI-921 raising the possibility of neurotoxicity.

Although drug-induced cardiotoxicity has been reported with the parent drug amsacrine, there was no evidence of this in the current study.

It has been suggested that CI-921 undergoes hepatic metabolism and biliary excretion following conjugation with glutathione. There was no fall in whole blood glutathione levels in patients following CI-921 infusion, although a transient decrease in mouse hepatic GSH was demonstrated following both amsacrine and CI-921. The toxicity of CI-921 in mice was markedly increased following depletion of hepatic glutathione with BSO but was not affected by pre-treatment with morphine or the glutathione "protector" N-acetyl cysteine.

CONTENTS

	page
Abstract	i
Contents	iii
Acknowledgements	iv
Glossary of abbreviations	vi
List of figures	ix
List of tables	xiii
List of appendices	xvi
Chapter 1 - Introduction and literature review	1
Chapter 2 - Phase I clinical trial	72
Chapter 3 - Phase II clinical trial in non-small cell lung cancer	90
Chapter 4 - Pharmacokinetic studies	104
Chapter 5 - The assessment of CI-921 for cardiotoxicity	153
Chapter 6 - Metabolic studies	172
Chapter 7 - Conclusions	220
Appendices	228
References	252
Associated publications	295

ACKNOWLEDGEMENTS

This work was supported in part by grants from the Auckland division of the Cancer Society of N.Z., the Medical Research Council of N.Z., and the Park-Davis Pharmaceutical Division, Warner-Lambert company, Ann Arbor, Michigan, U.S.A. (who also kindly supplied the CI-921 for use in these trials).

I am indebted to the patients who took part in these studies in the knowledge that CI-921 was unlikely to help them personally and to the nursing staff who cared for them, especially staff nurse Shelba Smith. I wish to thank my principal supervisor, Dr V.J. Harvey, without whose enthusiastic help and encouragement this work could never have been undertaken.

Dr Baguley is the Director of the Cancer Research Laboratory in which both amsacrine and CI-921 were developed. I am very grateful to have had the opportunity of working in association with Dr Baguley and his team and hope that the "bridging" between clinical and laboratory cancer research will continue.

To Dr J. Paxton and Professor D. Paton who appointed me as honorary research fellow in the Department of Pharmacology, I offer special thanks.

Christine Thoreau provided expert assistance in the animal studies and Dr Margaret Sage kindly prepared and reported on the histological sections.

I am very grateful to Dr W. Wilson for providing the equipment, information, advice and materials necessary for the glutathione studies.

Sincere thanks to my mother Joan Hardy and to Jill Simpson and Noeline Pou for the preparation of this manuscript.

Most special thanks to Pandora Evans, my friend and mentor, whose technical, emotional and social support throughout this study was invaluable.

GLOSSARY OF ABBREVIATIONS

AGC	absolute granulocyte count
ALP	alkaline phosphatase
AST	aspartate transferase
AUC	area under the concentration time curve
AUMC	area under the first moment of the concentration/time curve
BSO	buthionine sulfoximine
β	slope of the terminal portion of the log concentration/time curve
cf	compared with
CHO	chinese hamster ovary
CCNU	1-(-2-chloroethyl)-3-cyclohexyl-1-nitrosourea
CL	plasma clearance
C _{max}	maximum concentration achieved in plasma
CNS	central nervous system
C _t	concentration at last time point
cv	coefficient of variation
DEM	diethyl maleate
DNA	deoxyribose nucleic acid
ECOG	Eastern co-operative oncology group
EORTC	European organization for research and the treatment of cancer
FS	fractional shortening
g/dl	grams per deciliter

GSH	glutathione (reduced form)
GSSH	glutathione (oxidized form)
HPLC	high performance liquid chromatography
%ILS	percent increased life span
i.c.	intra-cerebral
i.p.	intra-peritoneal
I.S.	internal standard
i.v.	intra-venous
Ka	association constant
LD ₁₀	lethal dose in 10% of treated mice
LD ₅₀	lethal dose in 50% of treated mice
LD ₉₀	lethal dose in 90% of treated mice
LVEF	left ventricular ejection fraction
m-AQDI	quinine diimine of amsacrine
m-AQI	quinine monoimine of amsacrine
mg/m ²	milligrams per square metre (surface area)
MIS	misonidazole
MTD	maximum tolerated dose
NAC	N-acetyl cysteine
NCI	National Cancer Institute
NSCLC	non-small lung cancer
P	probability
PCV	packed cell volume

QSAR	quantitative-molecular-structure-activity-relationship
QTc	corrected Q-T interval of electrocardiogram
r	Pearson's correlation coefficient
s.c.	subcutaneous
SC	seeded quality control (plasma)
SCU	seeded quality control (urine)
STI	systolic time interval
TEAP	triethylamine phosphate
$t_{1/2\alpha}$	distribution half-life
$t_{1/2\beta}$	terminal half-life
UE	urinary excretion
Tt	last time point
Vss	volume of distribution

LIST OF FIGURES

		Page
FIGURE 1	CI-921	4
FIGURE 2	Amsacrine	5
FIGURE 3	Comparative structures of CI-921 and amsacrine	6
FIGURE 4	The metabolism of amsacrine	12
FIGURE 5	Intercalation of drug between base-pairs and subsequent distortion of the DNA helix	14
FIGURE 6	Mechanism of topoisomerase-mediated DNA cleavage by amsacrine and related drugs	19
FIGURE 7	The chemical structure of glutathione	64
FIGURE 8	Pathway of synthesis and metabolism of glutathione	66
FIGURE 9	Glutathione oxidation reduction cycle	66
FIGURE 10	Sample HPLC tracing for CI-921 and internal standard (IS)	113
FIGURE 11	Sample standard curve for back-calculation of CI-921 standards during assay validation	115
FIGURE 12	Plasma CI-921 concentration after the first day infusion over the dose range in three patients	121
FIGURE 13	Relationship between pharmacokinetic parameters and dose in individual patients	126
FIGURE 13.1	Relationship between dose and AUC of CI-921 after 65 infusions in 16 patients during a phase I trial	126

FIGURE 13.2	Relationship between dose and C _{max} of CI-921 after 65 infusions in 16 patients during a phase I trial	126
FIGURE 13.3	Relationship between dose and V _{ss} of CI-921 after 65 infusions in 16 patients during a phase I trial	127
FIGURE 13.4	Relationship between dose and CL of CI-921 after 65 infusions in 16 patients during a phase I trial	127
FIGURE 13.5	Relationship between dose and MRT of CI-921 after 65 infusions in 16 patients during a phase I trial	128
FIGURE 13.6	Relationship between dose and $t_{1/2\beta}$ of CI-921 after 65 infusions in 16 patients during a phase I trial	128
FIGURE 14	Relationship between dose of CI-921 and percent unchanged drug excreted in urine	129
FIGURE 15	Relationship between toxicity (nadir absolute granulocyte count) and pharmacokinetic parameters	131
FIGURE 15.1	Relationship between toxicity of CI-921 and area under curve (AUC)	131
FIGURE 15.2	Relationship between toxicity of CI-921 and maximum plasma concentration	131
FIGURE 15.3	Relationship between toxicity of CI-921 and dose	132
FIGURE 16	Relationship between toxicity (nadir absolute granulocyte count) and pharmacokinetic parameters - Phase II	136
FIGURE 16.1	Relationship between toxicity and AUC	136
FIGURE 16.2	Relationship between toxicity and CL	136

FIGURE 16.3	Relationship between toxicity and C _{max}	137
FIGURE 17	Relationship between dose and mean area under the curve: protocol 921-1: single dose study	140
FIGURE 18	Relationship between dose and mean area under the curve; combined data for the 3 phase I study centres	141
FIGURE 19	Relationship between clearance and dose; combined data from 3 phase I study centres	142
FIGURE 20	The relationship between dose and pharmacokinetic parameters for individual patients	144
FIGURE 21	Baseline and post-treatment cardiac parameters following treatment with CI-921 - phase I clinical trial	160
FIGURE 22	Cardiac parameters of patient no. 005 over 6 cycles of CI-921	162
FIGURE 23	Baseline and post-treatment cardiac parameters following treatment with CI-921- phase II trial	165
FIGURE 24	Cardiac parameters of patient no. 025 over 5 cycles of CI-921	167
FIGURE 25	Standard curve for GSH assay	182
FIGURE 26	Whole blood GSH concentrations in patients receiving CI-921	192
FIGURE 27	Whole blood GSH concentrations in healthy controls	195
FIGURE 28	Mouse hepatic GSH following amsacrine	199
FIGURE 29	Mouse hepatic GSH following CI-921	200
FIGURE 30	Mouse hepatic GSH following BSO	202

FIGURE 31	Mouse hepatic GSH following morphine	204
FIGURE 32	Mean weight of surviving mice following treatment with CI-921 and amsacrine	205
FIGURE 33	Survival curves of mice following treatment with CI-921 at 40-60 mg/kg i.v.	206
FIGURE 34	Survival curves of mice following treatment with amsacrine at 30-60 mg/kg i.v.	207
FIGURE 35	Survival curves of mice pretreated with morphine, NAC and BSO compared to the survival of mice treated with CI-921 alone	208
FIGURE 36	Mean weight of surviving mice pretreated with BSO, morphine sulphate and N-acetyl cysteine prior to CI-921	209
FIGURE 37	Survival curves of mice following treatment with CI-921 and NAC compared to CI-921 alone	210

LIST OF TABLES

	Page
TABLE 1.1 LD ₅₀ values (mM) of CI-921 and related agents	35
TABLE 1.2 Activity against i.p. inoculated P388 leukaemia	36
TABLE 1.3 Activity against i.v. inoculated Lewis lung carcinoma	37
TABLE 1.4 Modified Fibonacci search scheme for dose escalation in a phase I study	48
TABLE 2.1 Dose escalation in the phase I trial	77
TABLE 2.2 Patient characteristics - Phase I clinical trial	79
TABLE 2.3 Frequency and grade of toxicity at dose levels ≥ 228 mg/m ² (total dose) - Phase I	81
TABLE 2.4 Dose escalation methods used in each of the three trial centres for the phase I study of CI-921	87
TABLE 2.4.1 Trial centre 1: single dose repeated every 3 weeks	87
TABLE 2.4.2 Trial centre 2: weekly dose for 3 consecutive weeks repeated every 5 weeks	88
TABLE 2.4.3 Trial centre 3: daily dose for 3 consecutive days repeated every 3 weeks	89
TABLE 3.1 Patient characteristics - Phase II clinical trial in NSCLC	94
TABLE 3.2 Haematological toxicity - Phase II	96
TABLE 3.3 Non-haematological toxicity - Phase II	97

TABLE 4.1.	Quality control of CI-921 plasma assay - Phase I	119
TABLE 4.2	Quality control of CI-921 plasma assay - Phase II	120
TABLE 4.3	Mean model-independent pharmacokinetic parameters in the phase I trial	122
TABLE 4.4	Mean ratios of day 3/day 1 pharmacokinetic parameters after the first and third infusion of a three-day course with increasing dose	123
TABLE 4.5	Mean (SD) kinetic parameters at increasing i.v. dose	124
TABLE 4.6	Relationship between dose (mg/m ²) and pharmacokinetic parameters - Phase I	125
TABLE 4.7	Relationship between toxicity (nadir absolute granulocyte count) and pharmacokinetic parameters - Phase I	130
TABLE 4.8	Mean model-independent pharmacokinetic parameters in the phase II trial	134
TABLE 4.9	Relationship between toxicity (nadir absolute granulocyte count) and pharmacokinetic parameters - Phase II	135
TABLE 4.10	Mean terminal half-life following day 1 and day 3 infusions	145
TABLE 5.1	Pre- and post-treatment cardiac parameters - Phase I	159
TABLE 5.2	Pre- and post-treatment cardiac parameters - Phase II	164
TABLE 6.1	GSH levels in whole blood of patients receiving CI-921	190
TABLE 6.2	GSH levels in whole blood of healthy controls	193

TABLE 6.3	GSH levels in whole blood of mice following CI-921	196
TABLE 6.4	Mouse hepatic GSH following amsacrine	197
TABLE 6.5	Mouse hepatic GSH following CI-921	198
TABLE 6.6	Mouse hepatic GSH following BSO	201
TABLE 6.7	Mouse hepatic GSH following morphine	203
TABLE 6.8	Pre-clinical toxicology studies	217

APPENDICES

		Page
APPENDIX 1.1	Performance status (ECOG)	229
APPENDIX 1.2	Consent form for phase I trial	230
APPENDIX 1.3	Toxicity grading	232
APPENDIX 1.4	Consent form for phase II trial	233
APPENDIX 1.5	Patient information sheet for phase II trial	234
APPENDIX 2.1	Assay validation. Back calculated concentrations of plasma standards	235
APPENDIX 2.2	Assay validation. Back calculated concentrations of seeded quality controls (SC) in plasma	237
APPENDIX 2.3	Assay validation. Back calculated concentrations of urine standards	238
APPENDIX 2.4	Assay validation. Back calculated concentrations of seeded quality controls (SCU) in urine	240
APPENDIX 3.1	Mean CI-921 pharmacokinetic parameters calculated from the first and third infusion after different doses in all patients in the phase I trial	241
APPENDIX 3.2	CI-921 pharmacokinetic parameters calculated from the first infusion (216 mg/m ²) - phase II trial	243
APPENDIX 3.3	CI-921 pharmacokinetic parameters calculated from those patients in the phase I trial treated at 216 mg/m ²	244

APPENDIX 4.1.1	Mouse hepatic GSH concentration following amsacrine (Assay 1)	245
APPENDIX 4.1.2	Mouse hepatic GSH concentration following amsacrine (Assay 2)	246
APPENDIX 4.2.1	Mouse hepatic GSH concentration following CI-921 (Assay 3)	247
APPENDIX 4.2.2	Mouse hepatic GSH concentration following CI-921 (Assay 4)	248
APPENDIX 4.3.1	Mouse hepatic GSH concentration following BSO (Assay 5)	249
APPENDIX 4.3.2	Mouse hepatic GSH concentration following BSO (Assay 6)	250
APPENDIX 4.4	Mouse hepatic GSH concentration following morphine (Assay 7)	251

CHAPTER 1

INTRODUCTION AND LITERATURE REVIEW

	page
Preface	2
Amsacrine	
- Clinical efficacy	7
- Clinical toxicity	9
- Metabolism	10
- Pharmacokinetics	13
Mechanism of action of amsacrine - topoisomerase II	14
- Amsacrine and topoisomerase II	14
- The function of topoisomerase in the cell	16
- The interaction between topoisomerase and anti-neoplastic agents	18
The cardiotoxicity of amsacrine	23
The development of CI-921	
- QSAR in the design of CI-921	27
- Pre-clinical evaluation	33
Experimental tumour models and early clinical trials in the development of cytotoxic drugs	43
Non-small cell lung cancer and phase II trials	57
The relevance of pharmacokinetics in clinical trials	62
The metabolism of CI-921 - Glutathione	
- The role of glutathione in the cell	64
- The interaction of GSH with anti-neoplastic therapy	67
- The effect of changing GSH concentrations on anti-neoplastic therapy	68

PREFACE

Historically, the discovery of anti-neoplastic agents has been largely serendipitous, with the chance finding of cytotoxic activity in a natural product, or drug originally developed for some other purpose. Recently, there has been a more logical approach to the development of new anti-cancer agents by the chemical manipulation of compounds already known to have some activity. By changing various parts of a molecule to alter such physico-chemical properties as lipid solubility, stability and DNA binding strength, the aim is to improve the anti-neoplastic activity of the compound whilst preserving those parts of the molecule already known to confer a desired property. This is known as the quantitative molecular-structure-activity-relationship (or QSAR) approach to drug design.


The anilino-acridines were selected as potential anti-tumour agents in the early 1970s and following extensive QSAR studies of this series, amsacrine was developed and entered into clinical trial. By the early 1980s, amsacrine had been shown to be effective against haematological malignancies (Arlin 1983) but had no significant activity against solid tissue tumours in man (Zittoun 1985). Using the QSAR approach, it was hoped to produce a drug with both a wider spectrum of action and physico-chemical properties more suited to solid tumour activity. To this end hundreds of analogues of amsacrine were produced and tested against in vivo and in vitro tumour screens (Denny et al 1984).

The murine leukaemias L1210 and P388 were retained as convenient initial screens of cytotoxic activity but were used in association with the Lewis lung tumour model in an attempt to select out those agents with greater solid tumour activity. The Lewis lung system is a particularly valuable in vivo tumour model. It is one of the few murine tumour lines in the National Cancer Institute's tumour panel which differentiates those agents known to be active against solid tumours (for example cyclophosphamide, doxorubicin, 5-fluorouracil and methotrexate) and those known to be active against haematological malignancies (e.g. daunorubicin, cytosine arabinoside and L-asparaginase) (Goldin et al 1981). The agent showing the most cytotoxic activity against the Lewis lung tumour model whilst retaining its anti-leukaemic activity was the 4-methyl, 5-methyl carboxy derivative of amsacrine, known as CI-921 or "AMSALOG" (Baguley 1984) (Fig.1).

CI-921 is being developed by the Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company. Three phase I and limited phase II studies of CI-921 were undertaken in Puerto Rico, Ohio and Auckland, each centre giving the drug according to a different schedule. The phase I and II clinical and pharmacokinetic studies of CI-921 completed in Auckland form the basis of this thesis.

FIG. 1.

CI-921



Empirical formula: C₂₆H₃₀N₄S₂O₈

Molecular weight: 590.5 (monohydrate, 608.7)


Chemical name: 9-[[2-methoxy-4-[(methyl-sulfonyl) amino]-phenyl]amino]-N, 5-dimethyl-4-acridine-carboxamide, 2-hydroxyethane sulfonate (1:1)

Common name: "AMSALOG"

Other designations: CI-921
NSC 343,499.

FIG. 2.

Amsacrine



Empirical formula:	$C_{21}H_{19}N_3O_3S$
Molecular weight:	393.5
Chemical name:	N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide.
Common name:	m-AMSA, acridinyl anisidide.
Trade name:	Amsidine (Europe) Amsidyl (USA)
Other designations:	CI-880 NSC-249992.